Article Text

Download PDFPDF

AB0169 EARLY REMISSION AT 6 MONTHS AS A PREDICTOR OF LONGTERM REMISSION IN NEW ONSET RHEUMATOID ARTHRITIS
Free
  1. S. Emilie1,
  2. T. Sokolova1,
  3. A. Avramovska1,
  4. P. Sidiras2,
  5. S. Kleimberg2,
  6. S. Dierckx3,
  7. L. Meric de Bellefon4,
  8. C. Ribbens5,
  9. M. Malaise5,
  10. D. R. Silvana4,
  11. V. Badot6,
  12. P. Durez1
  1. 1Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium
  2. 2Hôpital Erasme, Rhumatologie, Brussels, Belgium
  3. 3CHU UCL Mont-Godinne, Rheumatology, Mont Godinne, Belgium
  4. 4CHU Saint–Pierre, Rheumatology, Brussels, Belgium
  5. 5CHU de Liège - Site Sart Tilman, Rheumatology, Liège, Belgium
  6. 6CHU Brugmann, Rheumatology, Brussels, Belgium

Abstract

Background Early therapeutic intervention is crucial for patients with early rheumatoid arthritis (ERA). The goal of remission is achievable in a large proportion of ERA patients.

Objectives To evaluate the rate of patients in remission at 6 months and to correlate the 36 and 60 months remission rate in the Belgian CAP48 cohort and the UCLouvain Brussels cohort. To identify baseline characteristics differences between patients achieving remission or not.

Methods We included patients with ERA from the CAP48 cohort and from the UCLouvain Brussels cohort who met the ACR/EULAR 2010 RA classification criteria. All patients were naïve to csDMARDs therapy. We collected patient characteristics at baseline and clinical response was analysed at 6, 36 and 60 months.

Results 287 RA patients from our UCLouvain Brussels Cohort and the CAP48 cohort were analysed (211 Females, 76 Males, mean age 46.2 years, 43.4% with baseline erosion, 70.1% with ACPA, 70.3% with Rheumatoid Factor, mean HAQ 1.16, mean DAS28-CRP 4.67, mean SDAI 24.9 and mean CDAI 24.1).

Table 1.

The clinical results are summarized in the Table.

In group 1 global remission (DAS28-CRP<2.6, HAQ<0.5 and no X-ray progression) was observed in 75.6% at 60 months. The majority of these patients (69.4%) are still treated with Methotrexate, the others were treated with combination therapy.

Conclusion Early and long term remission is an achievable goal in our two cohorts. Early diagnosis is critical in standard of care. At 6 months, all remission index criteria are good predictor for long term remission and could be used in daily care.

Disclosure of Interests None declared

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.